TITLE

Genmab Cuts 100 Jobs, Drops Pivotal CTCL Drug

PUB. DATE
October 2008
SOURCE
Bioworld Week;10/13/2008, Vol. 16 Issue 41, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the initiative of Genmab A/S to cut 15% of its work force by halting work on a Phase III program in cutaneous T-cell lymphoma. According to Lisa Drakeman, chief executive officer (CEO) of Genmab, they reduced its headcount by 101 employee, mostly from research and development (R&D). However, Drakeman claimed that costs associated with the restructuring would not have a material impact on Genmab's guidance for 2008.
ACCESSION #
34835732

 

Related Articles

  • Streamlining Genmab Cuts 100 Jobs, Drops Pivotal CTCL Drug. Boggs, Jennifer // BioWorld International;10/15/2008, Vol. 13 Issue 42, p4 

    The article reports on the decision of Danish antibody firm Genmab A/S to cut about 15 percent of its work force and halt work on a Phase III program in cutaneous T-cell lymphoma (CTCL). According to Genmab chief executive officer (CEO) Lisa Drakeman, the moves were necessary as the company's...

  • A Biotechnology Duo That Lives a Bicontinental Lifestyle.  // Business News New Jersey;7/31/2001, Vol. 14 Issue 31, p8 

    Features New Jersey power couple Donald and Lisa Drakeman. Personal background; Career highlights; Major achievements; Donald's role as chief executive officer (CEO) of Medarex; Lisa's role as CEO of Genmab.

  • Playing field in biotech/pharma partnerships levels. Drakeman, Lisa // Pharmaceutical Executive;May2005, Vol. 25 Issue 5, p44 

    The article presents an interview with Lisa Drakeman, CEO and co-founder of Genmab AS, on the partnership levels among the biotechnology companies and pharmaceutical companies. Some of the questions were, what is the difference between co-development and co-marketing, how have the inner workings...

  • Right retention.  // European Pharmaceutical Executive;Sep2007, p9 

    The article reports that Genmab A/S has regained its rights to the HuMax-TAC antibody from Merck Serono SA. Genmab is not expecting any changes on its financial guidance for 2007, as a result of the regained rights. Dr. Lisa N. Drakeman, chief executive officer of Genmab, also announces the...

  • Genmab CEO Drakeman Steps Down; CSO Takes the Helm. Sheridan, Cormac // BioWorld International;6/16/2010, Vol. 15 Issue 24, p1 

    The article announces the resignation of Lisa Drakeman, chief executive officer (CEO) of antibody developer Genmab A/S.

  • Flurry of Antibody M&A, but Genmab Left Out in the Cold. Boggs, Jennifer // BioWorld Insight;7/12/2010, Vol. 18 Issue 28, p2 

    The article reports that the Phase II clinical trial for Genmab A/S's anti-CD20 candidate ofatumumab has scored a positive hit for multiple sclerosis. However, its clinical success can unlikely impact the firm's restructured deal with GlaxoSmithKline which planned to eliminate future milestones...

  • Ofatumumab Misses NHL Mark; Genmab Shares Take a Tumble. Sheridan, Cormac // BioWorld Today;8/19/2009, Vol. 20 Issue 159, p1 

    The article reports on the decline in the shares of Genmab A/S on news that its antibody ofatumumab failed to show an objective response rate in non-Hodgkins lymphoma (NHL) patients. It relates that the overall response rate in the high dose arm of the study was 10 percent. It presents remarks...

  • GSK and Genmab file biologics license application for leukemia drug.  // PharmaWatch: Cancer;Mar2009, Vol. 8 Issue 3, p8 

    The article reports on the submission of a biologics license application by GlaxoSmithKline (GSK) and Genmab A/S for the leukemia drug Arzerra, also known as ofatumumab, to the U.S. Food and Drug Administration. It explains the implication of the move as well as provides an overview of the...

  • GSK and Genmab file marketing authorization application for leukemia drug.  // PharmaWatch: Cancer;Mar2009, Vol. 8 Issue 3, p9 

    The article reports on the submission of a marketing authorization application by GlaxoSmithKline (GSK) and Genmab A/S for the leukemia drug Arzerra, also known as ofatumumab, to the European Medicines Agency. It discusses the possible impact of the approval of the drug's commercialization...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics